Jupiter Topco LLC Takes $30.62 Million Position in Enliven Therapeutics, Inc. $ELVN

Jupiter Topco LLC purchased a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the second quarter, HoldingsChannel.com reports. The fund purchased 604,122 shares of the company’s stock, valued at approximately $30,617,000.

Several other large investors have also made changes to their positions in ELVN. Invesco Ltd. increased its stake in Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after acquiring an additional 913 shares during the last quarter. BNP Paribas Financial Markets raised its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. KBC Group NV acquired a new position in Enliven Therapeutics during the first quarter valued at approximately $38,000. Swiss National Bank lifted its stake in Enliven Therapeutics by 1.7% during the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Quantbot Technologies LP lifted its stake in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $57.86 on Friday. The firm’s fifty day moving average price is $54.62 and its two-hundred day moving average price is $43.10. The stock has a market cap of $4.24 billion, a PE ratio of -34.65 and a beta of 0.27. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the sale, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at approximately $2,345,308.88. This trade represents a 13.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the sale, the director owned 87,373 shares in the company, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 196,849 shares of company stock valued at $11,344,257 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ELVN. The Goldman Sachs Group lifted their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Barclays began coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price objective for the company. William Blair initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating on the stock. Mizuho boosted their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Finally, HC Wainwright increased their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $75.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.